The share jumped 6.6% on Wednesday after HSBC upgraded it from Hold to Buy and Goldman Sachs confirmed its Buy recommendation.
The renewed FDA submission for Awiqli, the world's first weekly basal insulin, is exciting. This not only gives Novo Nordisk an advantage over Eli Lilly, but could also generate new sales. At the same time, the Group is pulling the plug on less lucrative projects, such as the cooperation with Heartseed, and concentrating on its core business with diabetes and obesity. Global expansion is underway with the approval of Ozempic in India. $NOVO B (+1,65%)
https://www.boerse-express.com/news/articles/novo-nordisk-aktie-fantastische-bilanzzahlen-829890
